| http://www.w3.org/ns/prov#value | - Although preliminary, healthcare professionals starting patients on androgen deprivation therapy should be aware of these important findings, including the fact that the observed difference in cardiovascular risk in patients with baseline CVD was approximately 50 percent lower for Firmagon vs. LHRH agonists.???Renal, urinary tract and musculoskeletal adverse events (AEs)The treatment groups were a
|
